Biopharmaceutical company Hansa Medical AB (STO:HMED) announced on Tuesday that at the extraordinary general meeting, held on 11 December 2018, it was resolved to change Hansa Medical's company name to Hansa Biopharma AB, in accordance with the board of directors' proposal.

According to the company, this new name Hansa Biopharma emphasises its focus on the development and commercialisation of biological drugs, biopharmaceuticals.

Also, this refinement of its profile is particularly important for the continued internationalisation of the company's business and its investor base.

On 11 December 2018, the company has further submitted the resolution and the new company name for registration to the Swedish Companies Registration Office. The launch of the company's new name, including updated web page and graphical profile, is expected to take place on or about the beginning of 2019.

Hansa Medical is developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases.